November 23, 2021
2 min watch
Save
VIDEO: Xipere to be available in first quarter of 2022
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, discusses Xipere (triamcinolone acetonide injectable suspension).
The therapy, from Bausch + Lomb and Clearside Biomedical, was recently approved as a suprachoroidal injection for the treatment of macular edema secondary to uveitis, Barnard said.
Published by:
Sources/Disclosures
Collapse
Source:
Yolande Barnard
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.